Literature DB >> 30666589

Carfentanil: a narrative review of its pharmacology and public health concerns.

Jessica L S Leen1, David N Juurlink2,3,4,5.   

Abstract

Carfentanil is a synthetic fentanyl analogue approved for veterinary use. It is a mu-opioid receptor agonist with an estimated analgesic potency approximately 10,000 times that of morphine and 20-30 times that of fentanyl, based on animal studies. Since 2016, an increasing number of reports describe detection of carfentanil in the illicit drug supply. Little is known about the pharmacology of carfentanil in humans. Its high potency and presumed high lipophilicity, large volume of distribution, and potential active metabolites have raised concerns about the management of people exposed to carfentanil as well as the safety of first responders. Exposed individuals exhibit features of an opioid toxidrome and respond to opioid antagonists such as naloxone, although empiric dose requirements are unknown and very high doses may be required. Rare reports of suspected accidental poisoning of first responders have not been analytically confirmed and are unlikely to represent true poisoning. General occupational hygiene measures, including regular decontamination with soap and water, basic personal protective equipment (nitrile gloves, N95 mask, and eye goggles), and ready access to naloxone are generally sufficient in most circumstances.

Entities:  

Year:  2019        PMID: 30666589     DOI: 10.1007/s12630-019-01294-y

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  12 in total

1.  Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

Authors:  Lauren C Smith; Paul T Bremer; Candy S Hwang; Bin Zhou; Beverly Ellis; Mark S Hixon; Kim D Janda
Journal:  J Am Chem Soc       Date:  2019-06-25       Impact factor: 15.419

2.  Synthesis and μ-Opioid Activity of the Primary Metabolites of Carfentanil.

Authors:  Fu-Lian Hsu; Andrew J Walz; James M Myslinski; Li Kong; Michael G Feasel; Tyler D P Goralski; Tim Rose; Nicholas J Cooper; Neil Roughley; Christopher M Timperley
Journal:  ACS Med Chem Lett       Date:  2019-10-16       Impact factor: 4.345

Review 3.  Developmental opioid exposures: Neurobiological underpinnings, behavioral impacts, and policy implications.

Authors:  Samantha S Goldfarb; Gregg D Stanwood; Heather A Flynn; Devon L Graham
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-20

4.  Frequently asked questions about naloxone: Part 3.

Authors:  Ashley Cid; Alec Patten; Kelly Grindrod; Michael A Beazely
Journal:  Can Pharm J (Ott)       Date:  2021-11-05

Review 5.  Blood concentrations of new synthetic opioids.

Authors:  Piotr Adamowicz; Karolina Nowak
Journal:  Int J Legal Med       Date:  2021-10-22       Impact factor: 2.686

6.  Occupational Safety and Health and Illicit Opioids: State of the Research on Protecting Against the Threat of Occupational Exposure.

Authors:  Casey Basham; Audrey Cerles; Margaret Rush; Marissa Alexander-Scott; Lee Greenawald; Sophia Chiu; Kendra Broadwater; Deborah Hirst; John Snawder; Jennifer Roberts; Angela Weber; Martha Knuth; Rocco Casagrande
Journal:  New Solut       Date:  2021-08-18

Review 7.  Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.

Authors:  Randy Torralva; Aaron Janowsky
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

8.  A deadly trend in fentanyl fatalities (England, 1998-2017).

Authors:  Hugh Claridge; Bryn D Williams; Caroline S Copeland
Journal:  Br J Clin Pharmacol       Date:  2020-01-23       Impact factor: 4.335

9.  A Highly Efficacious Carfentanil Vaccine That Blunts Opioid-Induced Antinociception and Respiratory Depression.

Authors:  Lisa M Eubanks; Steven Blake; Yoshihiro Natori; Beverly Ellis; Paul T Bremer; Kim D Janda
Journal:  ACS Chem Biol       Date:  2021-02-03       Impact factor: 5.100

10.  Online surveillance of novel psychoactive substances (NPS): Monitoring Reddit discussions as a predictor of increased NPS-related exposures.

Authors:  Elan Barenholtz; Alex J Krotulski; Paul Morris; Nicole D Fitzgerald; Austin Le; Donna M Papsun; Barry K Logan; William E Hahn; Bruce A Goldberger; Linda B Cottler; Joseph J Palamar
Journal:  Int J Drug Policy       Date:  2021-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.